176 related articles for article (PubMed ID: 12411325)
1. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.
Laverdière C; Chiasson S; Costea I; Moghrabi A; Krajinovic M
Blood; 2002 Nov; 100(10):3832-4. PubMed ID: 12411325
[TBL] [Abstract][Full Text] [Related]
2. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
[TBL] [Abstract][Full Text] [Related]
3. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.
Levy AS; Sather HN; Steinherz PG; Sowers R; La M; Moscow JA; Gaynon PS; Uckun FM; Bertino JR; Gorlick R;
J Pediatr Hematol Oncol; 2003 Sep; 25(9):688-95. PubMed ID: 12972803
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
5. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
[TBL] [Abstract][Full Text] [Related]
6. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia.
Wang SM; Sun LL; Zeng WX; Wu WS; Zhang GL
Med Oncol; 2014 Jul; 31(7):62. PubMed ID: 24927955
[TBL] [Abstract][Full Text] [Related]
7. The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia.
Oosterom N; Fiocco M; Kloos RQH; van der Sluis IM; Pieters R; van Zelst BD; Smith DEC; van den Heuvel-Eibrink MM; de Jonge R; Heil SG
BMC Cancer; 2020 Sep; 20(1):940. PubMed ID: 32998716
[TBL] [Abstract][Full Text] [Related]
8. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
9. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.
Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
Leuk Res; 2018 Feb; 65():61-66. PubMed ID: 29306656
[TBL] [Abstract][Full Text] [Related]
10. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
11. Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia.
Faganel Kotnik B; Dolzan V; Grabnar I; Jazbec J
Leuk Lymphoma; 2010 Apr; 51(4):724-6. PubMed ID: 20141435
[No Abstract] [Full Text] [Related]
12. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
13. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.
Kaufman Y; Drori S; Cole PD; Kamen BA; Sirota J; Ifergan I; Arush MW; Elhasid R; Sahar D; Kaspers GJ; Jansen G; Matherly LH; Rechavi G; Toren A; Assaraf YG
Cancer; 2004 Feb; 100(4):773-82. PubMed ID: 14770434
[TBL] [Abstract][Full Text] [Related]
14. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
den Hoed MA; Lopez-Lopez E; te Winkel ML; Tissing W; de Rooij JD; Gutierrez-Camino A; Garcia-Orad A; den Boer E; Pieters R; Pluijm SM; de Jonge R; van den Heuvel-Eibrink MM
Pharmacogenomics J; 2015 Jun; 15(3):248-54. PubMed ID: 25348617
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism G80A in the reduced folate carrier gene and its relationship to survival and risk of relapse in acute lymphoblastic leukemia.
Leyva-Vázquez MA; Organista-Nava J; Gómez-Gómez Y; Contreras-Quiroz A; Flores-Alfaro E; Illades-Aguiar B
J Investig Med; 2012 Oct; 60(7):1064-7. PubMed ID: 22914600
[TBL] [Abstract][Full Text] [Related]
16. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
17. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract][Full Text] [Related]
18. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.
Suthandiram S; Gan GG; Zain SM; Bee PC; Lian LH; Chang KM; Ong TC; Mohamed Z
Pharmacogenomics; 2014 Aug; 15(11):1479-94. PubMed ID: 25303299
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma.
Imanishi H; Okamura N; Yagi M; Noro Y; Moriya Y; Nakamura T; Hayakawa A; Takeshima Y; Sakaeda T; Matsuo M; Okumura K
J Hum Genet; 2007; 52(2):166-171. PubMed ID: 17180579
[TBL] [Abstract][Full Text] [Related]
20. Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.
Liu Y; Yin Y; Sheng Q; Lu X; Wang F; Lin Z; Tian H; Xu A; Zhang J
PLoS One; 2014; 9(1):e82681. PubMed ID: 24404132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]